Crossmark

Optimal biological dose: a systematic review in cancer phase I clinical trials

Published Online: 2021-01-13

Published Print: 2021-12

Authors

Fraisse, J.

Dinart, D.

Tosi, D.

Bellera, C.

Mollevi, C. http://orcid.org/0000-0003-4827-3684
Funding

Funding for this research was provided by:

Institut National Du Cancer (SHS-ESP 2015-164)
License Information

Text and Data Mining valid from 2021-01-13

Version of Record valid from 2021-01-13
More Information

Article History

Received: 15 April 2020

Accepted: 1 January 2021

First Online: 13 January 2021

Ethics approval and consent to participate

: NA

: NA

: The authors have declared no conflicts of interest.

Document is current